With the stated growth in our top line, combined with the disciplined expense management and continued leverage inherent in our business model, which we have demonstrated over the course of 2025.

Mar 2, 2026 / receipt, needs a key / Kevin Green, CFO | earnings call 2026-03-02 | transcript c24ae7e6-b0d4-41bd-92b3-f024676c97b9 | chars 16311-16506 | segment 16

you know as i mentioned on the opportunity to spend some time in the region at the annual med lab conference which is held in dubai and you know candidly the the most challenging hoops to jump through are ones that we've already cleared and that's receiving both FDA approval and MDR clearance. I'm sure you hear a lot about the onerous nature of the MDD to MDR transition and the fact that we have achieved that milestone in addition to the fact that we're the only path to reduce technology that has an FDA approval that really resonates with customers. in that region. They tend to take their cues from the AABB and look to the US in terms of technology adoption. So that's sort of the major driver of the community and market interest there. It also is tied to an overall, as you're probably aware of, investment strategy in Saudi in particular, where they recognize there's a sort of a defined runway in terms of their economy being driven by natural resources. So they're investing in healthcare, they're investing in and entertainment and the rest. So there's a big push to invest in healthcare and there's a view to what technologies are approved in the U.S. and NBR cleared as things that they want to bring in locally. And so those are some of the factors that accrue to our benefit when we think about growth in that region.

May 2, 2024 / receipt, needs a key / Vivek, other | earnings call 2024-05-02 | transcript 56e1fdf6-059c-454c-96de-a40a35a0ac85 | chars 24962-26297 | segment 24

Having said that, we would expect to see some modestly higher expenses during the second half of the year, driven by higher labor costs, increased travel for customer and marketing-related activities, and higher prices from certain vendors.

Aug 4, 2022 / receipt, needs a key / Kevin Green, CFO | earnings call 2022-08-04 | transcript 0baeaf30-e49e-4de6-8589-c9f29e7b7745 | chars 12636-12876 | segment 12

But beyond that, we do expect that we'll return to more customer-facing travel, more in-person trade shows and marketing events. And so that's where I think you're going to see some of the costs tick up slightly from 2021 levels.

Feb 22, 2022 / receipt, needs a key / Kevin, CFO | earnings call 2022-02-22 | transcript 1e7207a1-1510-4191-b6a0-189887ba4bca | chars 29092-29321 | segment 28

Our Intercept technology can also improve donor eligibility by alleviating the need for certain donor deferrals, like travel-related deferrals designed to minimize the risk of malaria transmission.

Aug 3, 2021 / receipt, needs a key / Obie Greenman, CEO | earnings call 2021-08-03 | transcript 2eb9a059-8521-4c93-a786-966a728539ba | chars 8621-8818 | segment 8

We've seen some residual deferrals due to COVID. We're starting to see increased travel, hospital access, conference attendance, more in line with what we had expected.

Aug 3, 2021 / receipt, needs a key / Kevin, CFO | earnings call 2021-08-03 | transcript 2eb9a059-8521-4c93-a786-966a728539ba | chars 23203-23371 | segment 23

On a quarterly and annual basis, SG&A expenses were slightly lower than they would have otherwise been, driven by lower travel and marketing related expenses as a result of the COVID-19 pandemic.

Feb 25, 2021 / receipt, needs a key / Kevin, CFO | earnings call 2021-02-25 | transcript 33eb3142-2cdc-4235-be2f-8c2721a97de4 | chars 16565-16760 | segment 17

2026 product revenue guidance range: $229 million to $231 million*

ir_statement / Sep 14, 2026 / receipt

2026 IFC revenue guidance updated by Cerus on and as of July 30, 2026.

ir_statement / Sep 14, 2026 / receipt

Expect to deliver P&L leverage in 2026

ir_statement / Sep 14, 2026 / receipt

Q2:26 Operating Expenses of $37.3 million compared to $40.1 million for Q2:25.

ir_statement / Sep 14, 2026 / receipt

R&D expenses: $14.4 million, down 24% Y//Y

ir_statement / Sep 14, 2026 / receipt

Enterprise Accounts Hospital Sales Director | {"ats": "greenhouse", "city": null, "state": null, "job_id": "5232754007", "remote": true, "category": "sales_expansion", "function": "sales", "location":

company_statement / Sep 10, 2026 / receipt

Technical Operations Manager CMC | {"ats": "greenhouse", "city": "Concord", "state": "CA", "job_id": "5204422007", "remote": false, "category": "other", "function": "operations", "location": "Concord,

company_statement / Aug 19, 2026 / receipt

IT Portfolio & Project Manager | {"ats": "greenhouse", "city": "Concord", "state": "CA", "job_id": "5185559007", "remote": false, "category": "other", "function": "engineering", "location": "Concord,

company_statement / Jul 14, 2026 / receipt

Controller | {"ats": "greenhouse", "city": "Concord", "state": "CA", "job_id": "5179306007", "remote": false, "category": "finance_ops", "function": "finance", "location": "Concord, California", "job_

company_statement / Jul 6, 2026 / receipt

Quality Assurance Engineer III | {"ats": "greenhouse", "city": "Concord", "state": "CA", "job_id": "5174669007", "remote": false, "category": "other", "function": "engineering", "location": "Concord,

company_statement / Jul 1, 2026 / receipt

Marketing Director | {"ats": "greenhouse", "city": "Concord", "state": "CA", "job_id": "5158216007", "remote": false, "category": "other", "function": "marketing", "location": "Concord, California", "

company_statement / Jun 23, 2026 / receipt

Cerus Talent Community | {"ats": "greenhouse", "city": "Concord", "state": "CA", "job_id": "4096837007", "remote": false, "category": "other", "function": "hr", "location": "Concord, CA", "job_title":

company_statement / Oct 26, 2023 / receipt